Resistance map

Where resistance comes from in the hospital's catchment, and how the hospital compares with Europe. The regional view uses the patients' home areas in the laboratory extract; the European view uses national EARS-Net figures published by ECDC.

Regional view

Indicator Organism Antibiotic Ward Specimen

Period

Last 4 weeksLast 12 months

Date

European view

EARS-Net indicator

Catchment areas · % of Escherichia coli resistant to ceftriaxone

2023-12-17 → 2024-12-15 · first isolates

Synthetic areas: the extract only gives five abstract home areas around Tyks (Turku). The layout below is schematic, not real municipal borders.

Compare this organism across wards in the resistance view →

% (classes adapt to the selection)

10+

fewer than 30 isolates: not reported

All areas

3.4 %

n = 2849 · hover an area for details

Area	First isolates	Tested	Value	95 % CI
North	877	877	3.0 %	2–4 %
West	325	325	3.7 %	2–6 %
Centre	383	383	2.3 %	1–4 %
East	389	389	5.7 %	4–8 %
South	875	875	3.3 %	2–5 %

Europe · E. coli resistant to 3rd-generation cephalosporins

EARS-Net 2024 · invasive isolates

% of invasive E. coli isolates (blood, CSF) resistant to cefotaxime, ceftriaxone or ceftazidime.

% resistant

25+

outside EARS-Net / no data

Tyks extract vs Finland

This dataset 4.2 %

4/95 first blood isolates, 2023-12-17 → 2024-12-15 · 95 % CI 1.6–10.3 %

Finland (national) 7.5 %

EARS-Net 2024, n = 4,132

EU/EEA mean 16.0 %

Dataset: ceftriaxone-resistant E. coli from blood cultures (EARS-Net counts any of cefotaxime, ceftriaxone or ceftazidime). The extract is synthetic: the comparison shows the method, not Tyks' real level.

Source: ECDC EARS-Net, Antimicrobial resistance - Annual Epidemiological Report - Country summaries - 2024 data (published 2025-11-18), via ECDC EARS-Net. Values are shipped in data/ears-net.csv. Liechtenstein reported too few isolates.